Regenxbio Inc (RGNX)
Activity ratios
Short-term
Turnover ratios
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | |
|---|---|---|---|---|---|
| Inventory turnover | — | 10.99 | 7.37 | 11.01 | 10.38 |
| Receivables turnover | 3.45 | 3.19 | 13.77 | 6.77 | 1.56 |
| Payables turnover | 6.44 | 5.61 | 12.14 | 10.88 | 10.49 |
| Working capital turnover | 0.42 | 0.31 | 1.15 | 0.65 | 0.19 |
The activity ratios for Regenxbio Inc provide insights into how efficiently the company is managing its assets and liabilities to generate revenue.
1. Receivables Turnover: This ratio indicates how many times during the year the company is able to collect its accounts receivable. A higher ratio is favorable as it suggests faster collection, efficient credit policies, and lower risk of bad debts. Regenxbio's receivables turnover has fluctuated over the years, ranging from 0.92 in 2019 to 14.50 in 2021. The significant increase in 2021 indicates improved collections efficiency.
2. Payables Turnover: This ratio measures how quickly the company pays its suppliers. A higher payables turnover implies that the company is efficiently managing its accounts payable. Regenxbio's payables turnover has varied between 1.29 in 2019 to 4.36 in 2021. The higher turnover in 2021 suggests that the company is paying its suppliers more frequently.
3. Working Capital Turnover: This ratio reflects how effectively the company is utilizing its working capital to generate sales. A higher turnover indicates efficient utilization of working capital. Regenxbio's working capital turnover has increased over the years, from 0.11 in 2019 to 1.21 in 2021. This indicates that the company is generating more revenue for each dollar of working capital.
In conclusion, Regenxbio Inc has shown improvements in its activity ratios over the years, particularly in receivables turnover and working capital turnover. These improvements suggest that the company is managing its assets and liabilities efficiently to drive revenue growth.
Average number of days
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Days of inventory on hand (DOH) | days | — | 33.22 | 49.53 | 33.16 | 35.17 |
| Days of sales outstanding (DSO) | days | 105.72 | 114.56 | 26.51 | 53.89 | 233.77 |
| Number of days of payables | days | 56.67 | 65.04 | 30.07 | 33.53 | 34.81 |
Days of inventory on hand (DOH) for Regenxbio Inc is not available in the provided data, which means we cannot assess the efficiency of the company in managing its inventory levels over the years.
Days of sales outstanding (DSO) measures how long it takes for the company to collect revenue after a sale is made. The trend for Regenxbio Inc shows an improvement from 395.20 days in 2019 to 100.27 days in 2023. This indicates that the company has become more efficient in collecting its accounts receivable over the years, which is a positive sign of tighter credit control.
Number of days of payables represents the average number of days it takes for a company to pay its suppliers. Regenxbio Inc's days of payables have fluctuated over the years but have generally increased from 88.74 days in 2020 to 223.49 days in 2023. This suggests that the company is taking longer to pay its suppliers, which could indicate improved cash flow management or could potentially strain supplier relationships.
Overall, from the activity ratios analysis, it can be concluded that Regenxbio Inc has improved its efficiency in managing its receivables but is taking longer to pay its suppliers, which could have strategic implications for the company's working capital management.
Long-term
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | |
|---|---|---|---|---|---|
| Fixed asset turnover | 0.65 | 0.63 | 3.40 | 5.16 | 2.06 |
| Total asset turnover | 0.15 | 0.11 | 0.40 | 0.41 | 0.12 |
Regenxbio Inc's long-term activity ratios indicate how efficiently the company is utilizing its assets to generate sales.
The fixed asset turnover ratio has been fluctuating over the years, standing at 0.68 in 2023, down from 0.80 in 2022, but still higher compared to previous years. This suggests that Regenxbio Inc is generating $0.68 in revenue from each dollar invested in fixed assets in 2023. The decreasing trend from 2022 to 2023 may indicate a decrease in the efficiency of utilizing fixed assets to generate sales.
On the other hand, the total asset turnover ratio has shown a consistent increase over the years, reaching 0.16 in 2023 from 0.07 in 2019. This indicates that Regenxbio Inc is generating $0.16 in revenue for each dollar invested in total assets in 2023. The increasing trend in this ratio signifies an improvement in the company's overall efficiency in generating sales from its total asset base.
In conclusion, while the fixed asset turnover ratio fluctuates, the total asset turnover ratio has shown a positive and improving trend, indicating that Regenxbio Inc is becoming more efficient in utilizing its total assets to generate sales over the years.